Loading patent…
AssigneesSapporo Medical University, Nipro Corporation
InventorsOsamu HONMOU, Yoshihiro YOSHIKAWA, Ryo TOMII, Masafumi YAO, Yukari NISHII, Yusuke WAGATSUMA
Estimating the term…
The present invention relates to a cell-based medicine comprising mesenchymal stem cells, and a method for producing the same. More specifically, the present invention relates to: a cell-based medicine containing mesenchymal stem cells, wherein a) the mesenchymal stem cells express CX3CL1 under stimulation with an inflammatory cytokine, and/or b) 90% or more of the mesenchymal stem cells express EGFR and/or ITGA4; and a method for producing a cell-based medicine containing mesenchymal stem cells, the method comprising the steps of: a) adding an inflammatory cytokine to a culture containing mesenchymal stem cells, and confirming that the mesenchymal stem cells express CX3CL1; and/or b) confirming that 90% or more of the mesenchymal stem cells express EGFR and/or ITGA4.
A method for producing a cell-based medicine comprising mesenchymal stem cells, the method comprising the steps of:
-10. (canceled)
A method for evaluating the ability of a cell-based medicine comprising mesenchymal stem cells to accumulate at a site of injury, the method comprising a step of evaluating whether the expression of EGFR and/or ITGA4 in the mesenchymal stem cells is 90% or more.
A method for evaluating the ability of mesenchymal stem cells for a cell-based medicine, the method comprising the steps of:
Dependencies are inferred from the claim text.